Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Belgium | Colombia | Dominican Republic | Ecuador | Finland | Germany | Hungary | Italy | Mexico | Peru | Portugal | Slovenia | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Colgate Palmolive
Company Location: NEW YORK NY 10022
Company CEO: Noel R. Wallace
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Inflammation|Gingivitis
Phase 3: Dental Plaque
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05596149 | N/A |
Unknown status |
Other |
2023-02-01 |
|
CRO-2020-12-PGN-MMW-ITA-YPZ | P3 |
Completed |
Dental Plaque |
2021-09-24 |
38% |
16/YH/0015 | N/A |
Completed |
Pick Disease of the Brain|Dental Caries |
2017-05-31 |
|
PAR012015 | N/A |
Completed |
Gingivitis|Inflammation|Dental Plaque |
2016-02-01 |